Antares Pharma Inc (ATRS)

1.65
NASDAQ : Health Care
Prev Close 1.65
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.67 / 1.86
Avg Volume 783.10K
Exchange NASDAQ
Shares Outstanding 155.06M
Market Cap 257.40M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Significant Growth in Product Sales Drive Second Quarter Results

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc.

Antares Pharma Announces Settlement Of Patent Litigation For Key Alliance Business Product

Antares Pharma Announces Settlement Of Patent Litigation For Key Alliance Business Product

Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 21.61 "days to cover" versus the median component at 6.18.

Antares Pharma Announces Update To QuickShot Testosterone Clinical Program

Antares Pharma Announces Update To QuickShot Testosterone Clinical Program

Last Patient Completes Treatment in QuickShot Supplemental Safety Study QST-15-005

Short Interest Moves 16.5% Lower For ATRS

Short Interest Moves 16.5% Lower For ATRS

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 1,852,957 share decrease in total short interest for Antares Pharma Inc. , to 9,381,683, a decrease of 16.49% since 04/15/2016.

Antares Pharma Reports First Quarter 2016 Operating And Financial Results

Antares Pharma Reports First Quarter 2016 Operating And Financial Results

Total Revenues of $12.3 million increased 48% Over Q1 2015

Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Now Available - 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Stocks with insider trader activity include FLML, WLFC and ATRS

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 03/01/2016 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 19.06 "days to cover" versus the median component at 5.60.

Antares Pharma (ATRS) Stock Lower on Q4 Results

Antares Pharma (ATRS) Stock Lower on Q4 Results

Antares Pharma (ATRS) stock is decreasing on Tuesday morning after the company reported its 2015 fourth quarter results before today’s opening bell.

Antares Pharma Announces CEO Transition

Antares Pharma Announces CEO Transition

Robert Apple Appointed President and Chief Executive Officer

Antares Pharma Announces FDA Approval Of Sumatriptan Injection USP

Antares Pharma Announces FDA Approval Of Sumatriptan Injection USP

Antares' First ANDA Approval of a Therapeutically Equivalent Complex Generic Product

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades and moving much higher from current levels.